Mabion Past Earnings Performance
Past criteria checks 2/6
Mabion has been growing earnings at an average annual rate of 63.1%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 61% per year. Mabion's return on equity is 25.7%, and it has net margins of 26.7%.
Key information
63.1%
Earnings growth rate
63.5%
EPS growth rate
Biotechs Industry Growth | 56.3% |
Revenue growth rate | 61.0% |
Return on equity | 25.7% |
Net Margin | 26.7% |
Next Earnings Update | 25 Nov 2024 |
Recent past performance updates
Recent updates
Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 24Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For Growth
Nov 28Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue Forecasts
Jun 02Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?
Jul 09Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good News
Jun 04Is Mabion (WSE:MAB) Using Too Much Debt?
Dec 22Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate
Sep 11How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?
Feb 24Revenue & Expenses Breakdown
How Mabion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 140 | 37 | 49 | 3 |
31 Mar 24 | 146 | 42 | 42 | 5 |
31 Dec 23 | 152 | 41 | 40 | 6 |
30 Sep 23 | 148 | 58 | 39 | 8 |
30 Jun 23 | 157 | 42 | 35 | 14 |
31 Mar 23 | 165 | 32 | 31 | 15 |
31 Dec 22 | 164 | 23 | 29 | 15 |
30 Sep 22 | 156 | 45 | 34 | 8 |
30 Jun 22 | 117 | 34 | 34 | 9 |
31 Mar 22 | 75 | 26 | 32 | 8 |
31 Dec 21 | 36 | 2 | 30 | 14 |
30 Sep 21 | 2 | -51 | 21 | 28 |
30 Jun 21 | 2 | -45 | 20 | 24 |
31 Mar 21 | 0 | -53 | 20 | 30 |
31 Dec 20 | 0 | -56 | 19 | 34 |
30 Sep 20 | 0 | -55 | 17 | 36 |
30 Jun 20 | 0 | -63 | 18 | 40 |
31 Mar 20 | 0 | -69 | 21 | 43 |
31 Dec 19 | 0 | -64 | 21 | 41 |
30 Sep 19 | 0 | -65 | 22 | 40 |
30 Jun 19 | 0 | -59 | 21 | 39 |
31 Mar 19 | 0 | -70 | 20 | 45 |
31 Dec 18 | 0 | -69 | 20 | 45 |
30 Sep 18 | 0 | -72 | 23 | 48 |
30 Jun 18 | 0 | -74 | 23 | 49 |
31 Mar 18 | 0 | -59 | 22 | 41 |
31 Dec 17 | 0 | -58 | 21 | 43 |
30 Sep 17 | 0 | -56 | 18 | 43 |
30 Jun 17 | 0 | -57 | 16 | 47 |
31 Mar 17 | 0 | -59 | 15 | 47 |
31 Dec 16 | 0 | -56 | 13 | 44 |
30 Sep 16 | 0 | -77 | 11 | 71 |
30 Jun 16 | 0 | -65 | 9 | 59 |
31 Mar 16 | 3 | -51 | 8 | 48 |
31 Dec 15 | 3 | -43 | 5 | 40 |
30 Sep 15 | 3 | -6 | 4 | 0 |
30 Jun 15 | 3 | -5 | 3 | 0 |
31 Mar 15 | 1 | -5 | 2 | 0 |
31 Dec 14 | 1 | -4 | 1 | 0 |
30 Sep 14 | 1 | -4 | 4 | 0 |
30 Jun 14 | 0 | -4 | 4 | 0 |
31 Mar 14 | 0 | -4 | 4 | 0 |
31 Dec 13 | 0 | -4 | 4 | 0 |
Quality Earnings: MAB has a high level of non-cash earnings.
Growing Profit Margin: MAB's current net profit margins (26.7%) are lower than last year (27%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MAB has become profitable over the past 5 years, growing earnings by 63.1% per year.
Accelerating Growth: MAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MAB had negative earnings growth (-11.7%) over the past year, making it difficult to compare to the Biotechs industry average (-13.8%).
Return on Equity
High ROE: MAB's Return on Equity (25.7%) is considered high.